Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=4
{ "count": 24302, "next": "http://api.gregory-ms.com/articles/?format=api&page=5", "previous": "http://api.gregory-ms.com/articles/?format=api&page=3", "results": [ { "article_id": 283057, "title": "Pediatric traumatic brain injury and early age multiple sclerosis in Finland: A nationwide register‐based cohort study", "summary": "<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Examine the link between pediatric traumatic brain injury (pTBI) and early‐onset multiple sclerosis in Finland.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Conducted nationwide register study (1998−2018) with 28,750 pTBI patients (< 18) and 38,399 pediatric references with extremity fractures. Multiple sclerosis diagnoses from Finnish Social Insurance Institution. Employed Kaplan−Meier and multivariable Cox regression for probability assessment, results presented with 95% CI.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 66 post‐traumatic multiple sclerosis cases, 30 (0.10%) had pTBI, and 36 (0.09%) were in the reference group. Cumulative incidence rates (CIR) in the first 10 years were 46.5 per 100,000 (pTBI) and 33.1 per 100,000 (reference). Hazard ratio (HR) for pTBI was 1.10 (95% CI: 0.56−1.48).Stratified by gender, women's CIR was 197.9 per 100,000 (pTBI) and 167.0 per 100,000 (reference) after 15 years. For men, CIR was 44.6 per 100,000 (pTBI) and 34.7 per 100,000 (reference). In the initial 3 years, HR for female pTBI was 1.75 (95% CI: 0.05−6.32), and between years 3 and 20, it was 1.08 (95% CI: 0.51−1.67). For male patients, HR was 1.74 (95% CI: 0.69−4.39).</jats:p></jats:sec><jats:sec><jats:title>Significance</jats:title><jats:p>We did not find evidence of an association between pTBI and early‐onset multiple sclerosis 20 years post‐initial trauma.</jats:p></jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/38622897/?fc=20210216052009&ff=20240417062536&v=2.18.0.post9+e462414", "published_date": "2024-04-16T10:00:00Z", "source": "PubMed", "publisher": "Wiley", "container_title": "Brain and Behavior", "authors": [ { "author_id": 348298, "given_name": "Juho", "family_name": "Laaksonen", "ORCID": "http://orcid.org/0000-0002-9328-4721", "country": null }, { "author_id": 348299, "given_name": "Ville", "family_name": "Ponkilainen", "ORCID": null, "country": null }, { "author_id": 348300, "given_name": "Ilari", "family_name": "Kuitunen", "ORCID": null, "country": null }, { "author_id": 348301, "given_name": "Julius", "family_name": "Möttönen", "ORCID": null, "country": null }, { "author_id": 348302, "given_name": "Ville M.", "family_name": "Mattila", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T17:25:38.989393Z", "noun_phrases": null, "doi": "10.1002/brb3.3478", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 283056, "title": "The possible role of oxidative stress marker glutathione in the assessment of cognitive impairment in multiple sclerosis", "summary": "<jats:title>Abstract</jats:title>\n<jats:p>Oxidative stress markers have a distinct role in the process of demyelination in multiple sclerosis. This study investigated the potential correlation of markers of oxidative stress (glutathione [GSH], catalase) with the number of demyelinating lesions and the degree of disability, cognitive deficit, and depression in patients with relapsing-remitting multiple sclerosis (RRMS). Sixty subjects meeting the criteria for RRMS (19 men and 41 women), and 66 healthy controls (24 men, 42 women) were included. In this study, GSH significantly negatively correlated with the degree of cognitive impairment. This is the first study of subjects with RRMS that performed the mentioned research of serum GSH levels on the degree of cognitive damage examined by the Montreal Scale of Cognitive Assessment (MoCA) test. The development of cognitive changes, verified by the MoCA test, was statistically significantly influenced by the positive number of magnetic resonance lesions, degree of depression, expanded disability status scale (EDSS), age, and GSH values. Based on these results, it can be concluded that it is necessary to monitor cognitive status early in RRMS patients, especially in those with a larger number of demyelinating lesions and a higher EDSS level and in older subjects. Also, the serum level of GSH is a potential biomarker of disease progression, which could be used more widely in RRMS.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38623459/?fc=20210216052009&ff=20240417062536&v=2.18.0.post9+e462414", "published_date": "2024-04-16T10:00:00Z", "source": "PubMed", "publisher": "Walter de Gruyter GmbH", "container_title": "Open Medicine", "authors": [ { "author_id": 348263, "given_name": "Andrijana Bogoje", "family_name": "Raspopović", "ORCID": null, "country": null }, { "author_id": 348264, "given_name": "Vedran", "family_name": "Balta", "ORCID": null, "country": null }, { "author_id": 348265, "given_name": "Maro", "family_name": "Vodopić", "ORCID": null, "country": null }, { "author_id": 348266, "given_name": "Marina", "family_name": "Drobac", "ORCID": null, "country": null }, { "author_id": 348267, "given_name": "Almoš", "family_name": "Boroš", "ORCID": null, "country": null }, { "author_id": 348268, "given_name": "Domagoj", "family_name": "Đikić", "ORCID": "http://orcid.org/0000-0003-0909-3488", "country": null }, { "author_id": 348269, "given_name": "Vida", "family_name": "Demarin", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T17:25:37.847176Z", "noun_phrases": null, "doi": "10.1515/med-2024-0952", "access": "open", "takeaways": "Oxidative stress markers have a distinct role in the process of demyelination in multiple sclerosis. The development of cognitive changes was influenced by the positive number of magnetic resonance lesions, degree of depression, expanded disability status scale (EDSS), age and GSH values.", "categories": [] }, { "article_id": 283055, "title": "Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab", "summary": "<jats:p> Aim: To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. Methods: Patients enrolled in the MS PATHS network who initiated treatment with either natalizumab or ocrelizumab rated the Neuro-QoL domains of physical function, symptoms, emotional health, cognitive function and social ability. Results: Time to clinically meaningful improvement was significantly shorter with natalizumab versus ocrelizumab for cognitive function (event time ratio [95% CI]: 0.37 [0.24–0.57]; p < 0.001), sleep disturbance (0.45 [0.28–0.72]; p = 0.001), social role participation (0.37 [0.21–0.66]; p = 0.001) and social role satisfaction (0.5 [0.31–0.8]; p = 0.004). Conclusion: Natalizumab had shorter time to clinically meaningful improvement in cognitive, sleep, and social role Neuro-QoL domains versus ocrelizumab. </jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38623894/?fc=20210216052009&ff=20240417122553&v=2.18.0.post9+e462414", "published_date": "2024-04-16T10:00:00Z", "source": "PubMed", "publisher": "Informa UK Limited", "container_title": "Neurodegenerative Disease Management", "authors": [ { "author_id": 254659, "given_name": "Deborah M", "family_name": "Miller", "ORCID": null, "country": null }, { "author_id": 184311, "given_name": "Marisa P", "family_name": "McGinley", "ORCID": "http://orcid.org/0000-0002-7463-6787", "country": null }, { "author_id": 322671, "given_name": "Megan", "family_name": "Hyland", "ORCID": "http://orcid.org/0000-0001-8748-6370", "country": null }, { "author_id": 244210, "given_name": "Robin L", "family_name": "Avila", "ORCID": null, "country": null }, { "author_id": 185812, "given_name": "Carrie M", "family_name": "Hersh", "ORCID": "http://orcid.org/0000-0002-5716-5645", "country": null }, { "author_id": 348295, "given_name": "Menglan", "family_name": "Pang", "ORCID": null, "country": null }, { "author_id": 153754, "given_name": "Tjalf", "family_name": "Ziemssen", "ORCID": "http://orcid.org/0000-0001-8799-8202", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T17:25:36.930565Z", "noun_phrases": null, "doi": "10.2217/nmt-2023-0047", "access": "restricted", "takeaways": "Time to clinically meaningful improvement was significantly shorter with natalizumab versus ocrelizumac.", "categories": [ { "category_id": 7, "category_description": "", "category_name": "Natalizumab", "category_slug": "natalizumab", "category_terms": [ "natalizumab", "tysabri" ], "article_count": 298 }, { "category_id": 8, "category_description": "", "category_name": "Ocrelizumab", "category_slug": "ocrelizumab", "category_terms": [ "ocrelizumab", "ocrevus" ], "article_count": 224 } ] }, { "article_id": 283054, "title": "Highlight of 2023: big impacts of <scp>microRNAs</scp> in T cells", "summary": "In 2023, several significant discoveries on the function of microRNAs in the immune system were reported. Here we discuss several notable papers that revealed important functions in T cells.", "link": "https://pubmed.ncbi.nlm.nih.gov/38623898/?fc=20210216052009&ff=20240417122553&v=2.18.0.post9+e462414", "published_date": "2024-04-16T10:00:00Z", "source": "PubMed", "publisher": "Wiley", "container_title": "Immunology & Cell Biology", "authors": [ { "author_id": 348296, "given_name": "Yangnan", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 348297, "given_name": "Mark MW", "family_name": "Chong", "ORCID": "http://orcid.org/0000-0002-3701-7397", "country": "AU" } ], "relevant": null, "ml_prediction_gnb": true, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T17:25:36.111294Z", "noun_phrases": null, "doi": "10.1111/imcb.12753", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 283053, "title": "Patient perspectives about multiple sclerosis: A metaphor study", "summary": "<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>Determining patients' perceptions of multiple sclerosis, a disease with varying symptoms and prognosis for each individual, can significantly contribute to directing care and treatment. Metaphors may be an opportunity to determine perceptions of this unique illness experience. The aim of this study was to reveal the perceptions of patients with multiple sclerosis about “multiple sclerosis” through metaphors.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This study was conducted with metaphor analysis technique based on phenomenological method. The sample included 184 patients with multiple sclerosis. Data was collected face‐to‐face between July 2022 and January 2023. Each participant was interviewed individually and was asked to fill in the blanks in the sentence, “multiple sclerosis is like… because…”. Content analysis was performed for metaphors.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The study revealed five main themes and twelve subthemes that provided insight into the participants' multiple sclerosis perceptions. The themes address (i) Manipulator multiple sclerosis; ambiguous multiple sclerosis, attritive multiple sclerosis, controller multiple sclerosis, demander multiple sclerosis, and conditional multiple sclerosis (ii) Temporal multiple sclerosis; cyclical multiple sclerosis and perpetual multiple sclerosis (iii) Follower multiple sclerosis; unaccepted multiple sclerosis, partner multiple sclerosis and ambusher multiple sclerosis (iv) Different multiple sclerosis; bittersweet multiple sclerosis and unique multiple sclerosis (v) Restorative multiple sclerosis.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This study demonstrated that patients with multiple sclerosis mostly had negative perceptions regarding their relationship with multiple sclerosis. The results place a responsibility on healthcare professionals to improve how patients adapt to multiple sclerosis. This study's results can bridge theoretical knowledge and practice.</jats:p></jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/38623997/?fc=20210216052009&ff=20240417122553&v=2.18.0.post9+e462414", "published_date": "2024-04-16T10:00:00Z", "source": "PubMed", "publisher": "Wiley", "container_title": "Journal of Evaluation in Clinical Practice", "authors": [ { "author_id": 348260, "given_name": "Esra", "family_name": "Uslu", "ORCID": "http://orcid.org/0000-0003-0168-2747", "country": null }, { "author_id": 348261, "given_name": "Aysel", "family_name": "Özsaban", "ORCID": "http://orcid.org/0000-0002-8739-8829", "country": null }, { "author_id": 348262, "given_name": "Şahika", "family_name": "Ocak", "ORCID": null, "country": null }, { "author_id": 328777, "given_name": "Aysun", "family_name": "Bayram", "ORCID": "http://orcid.org/0000-0003-2038-6265", "country": null }, { "author_id": 184908, "given_name": "Serkan", "family_name": "Demir", "ORCID": "http://orcid.org/0000-0003-4395-5141", "country": "TR" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T17:25:35.090245Z", "noun_phrases": null, "doi": "10.1111/jep.13995", "access": "open", "takeaways": "Study was conducted with metaphor analysis technique based on phenomenological method. Data was collected face-to-face between July 2022 and January 2023 from 184 patients with multiple sclerosis. The study revealed five main themes and twelve subthemes that provided insight into participants' multiple sclerosis perceptions.", "categories": [] }, { "article_id": 283052, "title": "Dysregulated Lipid Metabolism Networks Modulate T-cell Function in People with Relapsing Remitting Multiple Sclerosis", "summary": "<jats:title>Abstract</jats:title>\n<jats:p>Altered cholesterol, oxysterol, sphingolipid, and fatty acid concentrations are reported in blood, cerebrospinal fluid, and brain tissue of people with relapsing remitting multiple sclerosis (RRMS) and are linked to disease progression and treatment responses. CD4+ T cells are pathogenic in RRMS, and defective T cell function could be mediated in part by liver X receptors (LXRs) - nuclear receptors that regulate lipid homeostasis and immunity. RNA-sequencing and pathway analysis identified that genes within the ‘lipid metabolism’ and ‘signalling of nuclear receptors’ pathways were dysregulated in CD4+ T cells isolated from RRMS patients compared with healthy donors. While LXRB and genes associated with cholesterol metabolism were upregulated, other T cell LXR-target genes, including genes involved in cellular lipid uptake (inducible degrader of the LDL receptor, IDOL), and the rate-limiting enzyme for glycosphingolipid biosynthesis (UDP-glucosylceramide synthase, UGCG) were downregulated in T cells from patients with RRMS compared to healthy donors. Correspondingly, plasma membrane glycosphingolipids were reduced, and cholesterol levels increased in RRMS CD4+ T cells, an effect partially recapitulated in healthy T cells by in vitro culture with T cell receptor stimulation in the presence of serum from RRMS patients. Notably, stimulation with LXR-agonist GW3965 normalised membrane cholesterol levels, and reduced proliferation and IL17 cytokine production in RRMS CD4+ T-cells. Thus, LXR-mediated lipid metabolism pathways were dysregulated in T cells from patients with RRMS and could contribute to RRMS pathogenesis. Therapies that modify lipid metabolism could help restore immune cell function.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38625017/?fc=20210216052009&ff=20240417122553&v=2.18.0.post9+e462414", "published_date": "2024-04-16T10:00:00Z", "source": "PubMed", "publisher": "Oxford University Press (OUP)", "container_title": "Clinical and Experimental Immunology", "authors": [ { "author_id": 348323, "given_name": "Lucia", "family_name": "Martin-Gutierrez", "ORCID": null, "country": null }, { "author_id": 348324, "given_name": "Kirsty E", "family_name": "Waddington", "ORCID": null, "country": null }, { "author_id": 348325, "given_name": "Annalisa", "family_name": "Maggio", "ORCID": null, "country": null }, { "author_id": 348326, "given_name": "Leda", "family_name": "Coelewij", "ORCID": null, "country": null }, { "author_id": 348327, "given_name": "Alexandra", "family_name": "Oppong", "ORCID": null, "country": null }, { "author_id": 348328, "given_name": "Nina", "family_name": "Yang", "ORCID": null, "country": null }, { "author_id": 348329, "given_name": "Marsilio", "family_name": "Adriani", "ORCID": null, "country": null }, { "author_id": 322820, "given_name": "Petra", "family_name": "Nytrova", "ORCID": "http://orcid.org/0000-0003-4885-602X", "country": null }, { "author_id": 252770, "given_name": "Rachel", "family_name": "Farrell", "ORCID": null, "country": null }, { "author_id": 252767, "given_name": "Inés", "family_name": "Pineda-Torra", "ORCID": null, "country": null }, { "author_id": 348330, "given_name": "Elizabeth C", "family_name": "Jury", "ORCID": "http://orcid.org/0000-0002-2389-3396", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T17:25:34.167235Z", "noun_phrases": null, "doi": "10.1093/cei/uxae032", "access": "restricted", "takeaways": "Altered cholesterol, oxysterol, sphingolipid, and fatty acid concentrations are reported in blood, cerebrospinal fluid, and brain tissue", "categories": [] }, { "article_id": 283051, "title": "Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis", "summary": "<jats:title>Abstract</jats:title><jats:sec>\n<jats:title>Background</jats:title>\n<jats:p>Increasingly, patients, clinicians, and regulators call for more evidence on the impact of innovative medicines on quality of life (QoL). We assessed the effects of disease-modifying therapies (DMTs) on QoL in people with multiple sclerosis (PwMS).</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Methods</jats:title>\n<jats:p>Randomized trials assessing approved DMTs in PwMS with results for at least one outcome referred to as “quality of life” were searched in PubMed and ClinicalTrials.gov.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Results</jats:title>\n<jats:p>We identified 38 trials published between 1999 and 2023 with a median of 531 participants (interquartile range (IQR) 202 to 941; total 23,225). The evaluated DMTs were mostly interferon-beta (<jats:italic>n</jats:italic> = 10; 26%), fingolimod (<jats:italic>n</jats:italic> = 7; 18%), natalizumab (<jats:italic>n</jats:italic> = 5; 13%), and glatiramer acetate (<jats:italic>n</jats:italic> = 4; 11%). The 38 trials used 18 different QoL instruments, with up to 11 QoL subscale measures per trial (median 2; IQR 1–3). QoL was never the single primary outcome. We identified quantitative QoL results in 24 trials (63%), and narrative statements in 15 trials (39%). In 16 trials (42%), at least one of the multiple QoL results was statistically significant. The effect sizes of the significant quantitative QoL results were large (median Cohen’s d 1.02; IQR 0.3–1.7; median Hedges’ g 1.01; IQR 0.3–1.69) and ranged between d 0.14 and 2.91.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Conclusions</jats:title>\n<jats:p>Certain DMTs have the potential to positively impact QoL of PwMS, and the assessment and reporting of QoL is suboptimal with a multitude of diverse instruments being used. There is an urgent need that design and reporting of clinical trials reflect the critical importance of QoL for PwMS.</jats:p>\n</jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/38625399/?fc=20210216052009&ff=20240417122553&v=2.18.0.post9+e462414", "published_date": "2024-04-16T10:00:00Z", "source": "PubMed", "publisher": "Springer Science and Business Media LLC", "container_title": "Journal of Neurology", "authors": [ { "author_id": 327167, "given_name": "Julian", "family_name": "Hirt", "ORCID": "http://orcid.org/0000-0001-6589-3936", "country": null }, { "author_id": 348309, "given_name": "Kinga", "family_name": "Dembowska", "ORCID": "http://orcid.org/0000-0001-6903-2826", "country": "CH" }, { "author_id": 167451, "given_name": "Tim", "family_name": "Woelfle", "ORCID": "http://orcid.org/0000-0001-6279-4158", "country": null }, { "author_id": 348310, "given_name": "Cathrine", "family_name": "Axfors", "ORCID": "http://orcid.org/0000-0002-2706-1730", "country": null }, { "author_id": 170634, "given_name": "Cristina", "family_name": "Granziera", "ORCID": "http://orcid.org/0000-0002-4917-8761", "country": "CH" }, { "author_id": 154809, "given_name": "Jens", "family_name": "Kuhle", "ORCID": "http://orcid.org/0000-0002-6963-8892", "country": "CH" }, { "author_id": 147953, "given_name": "Ludwig", "family_name": "Kappos", "ORCID": "http://orcid.org/0000-0003-4175-5509", "country": null }, { "author_id": 327170, "given_name": "Lars G.", "family_name": "Hemkens", "ORCID": "http://orcid.org/0000-0002-3444-1432", "country": "CH" }, { "author_id": 327168, "given_name": "Perrine", "family_name": "Janiaud", "ORCID": "http://orcid.org/0000-0001-7684-8014", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T17:25:33.343826Z", "noun_phrases": null, "doi": "10.1007/s00415-024-12366-5", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 283050, "title": "Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison", "summary": "<jats:title>Abstract</jats:title><jats:p>Emerging tumor immunotherapy methods encompass bispecific antibodies (BSABs), immune checkpoint inhibitors (ICIs), and adoptive cell immunotherapy. BSABs belong to the antibody family that can specifically recognize two different antigens or epitopes on the same antigen. These antibodies demonstrate superior clinical efficacy than monoclonal antibodies, indicating their role as a promising tumor immunotherapy option. Immune checkpoints are also important in tumor immunotherapy. Programmed cell death protein-1 (PD-1) is a widely acknowledged immune checkpoint target with effective anti-tumor activity. PD-1 inhibitors have demonstrated notable therapeutic efficacy in treating hematological and solid tumors; however, more than 50% of patients undergoing this treatment exhibit a poor response. However, ICI-based combination therapies (ICI combination therapies) have been demonstrated to synergistically increase anti-tumor effects and immune response rates. In this review, we compare the clinical efficacy and side effects of BSABs and ICI combination therapies in real-world tumor immunotherapy, aiming to provide evidence-based approaches for clinical research and personalized tumor diagnosis and treatment.</jats:p>", "link": "https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-024-01956-6", "published_date": "2024-04-15T23:00:00Z", "source": "BioMedCentral", "publisher": "Springer Science and Business Media LLC", "container_title": "Molecular Cancer", "authors": [ { "author_id": 348274, "given_name": "Linyan", "family_name": "Cheng", "ORCID": null, "country": null }, { "author_id": 348275, "given_name": "Lujun", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 300970, "given_name": "Yuan", "family_name": "Shi", "ORCID": null, "country": null }, { "author_id": 348276, "given_name": "Weiying", "family_name": "Gu", "ORCID": null, "country": null }, { "author_id": 348277, "given_name": "Weidong", "family_name": "Ding", "ORCID": null, "country": null }, { "author_id": 348278, "given_name": "Xiao", "family_name": "Zheng", "ORCID": null, "country": null }, { "author_id": 262338, "given_name": "Yan", "family_name": "Liu", "ORCID": null, "country": null }, { "author_id": 348279, "given_name": "Jingting", "family_name": "Jiang", "ORCID": null, "country": null }, { "author_id": 348280, "given_name": "Zhuojun", "family_name": "Zheng", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": true, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T16:27:58.559881Z", "noun_phrases": null, "doi": "10.1186/s12943-024-01956-6", "access": "open", "takeaways": "Tumor immunotherapy methods encompass bispecific antibodies (BSABs), immune checkpoint inhibitors (ICIs), and adoptive cell immunotherapy. BSABs belong to the antibody family that can specifically recognize two different antigens or epitopes on the same antigen. ICI-based combination therapies have been demonstrated to synergistically increase anti-tumor effects and", "categories": [] }, { "article_id": 283049, "title": "The relationship between serum resolvin D1, NLRP3, cytokine levels, and adolescents with first-episode medication-naïve major depressive disorder", "summary": "<jats:title>Abstract</jats:title><jats:sec>\n<jats:title>Background</jats:title>\n<jats:p>Inflammation has become a critical pathological mechanism of Major Depressive Disorder (MDD). NLRP3 is a critical inflammatory pathway to maintain the immune balance. Recently, preclinical evidence showed that Resolvin D1 might potentially offer a new option for antidepressant treatment due to its protective effects through the inhibition of neuroinflammation. However, whether they have clinical value in the diagnosis and treatment evaluation of adolescent depression was unclear.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Methods</jats:title>\n<jats:p>Forty-eight untreated first-episode adolescent patients with moderate to severe major depressive disorder, as well as 30 healthy adolescents (HCs, age and gender-matched), were enrolled for this study. Their ages ranged from 13 to 18 (15.75 ± 1.36) years. The patients were treated with fluoxetine for 6–8 weeks. HDRS-17 was used to evaluate the severity of depressive symptoms. Venous blood samples were collected at baseline for the two groups and at the time-point of post-antidepressant treatment for the patients. Serum concentrations of RvD1, NLRP3, IL-1β, IL-18, and IL-4 were measured by enzyme-linked immunosorbent assays (ELISA) pre- and post-fluoxetine treatment.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Results</jats:title>\n<jats:p>Serum levels of RvD1 and anti-inflammatory cytokine IL-4 were significantly elevated in adolescents with MDD compared to healthy adolescents, but no significant difference in NLRP3, IL-1β, and IL-18 between the two groups. Meanwhile, RvD1 (positively) and IL-4 (negatively) were correlated with the severity of symptoms (HDRS-17 scores) after adjusting age, gender, and BMI. Interestingly, fluoxetine treatment significantly reduced the serum levels of RvD1, NLRP3, IL-1β, and IL-18 in MDD adolescents but increased the levels of IL-4 relative to baseline. Furthermore, we observed that serum levels of RvD1 might be an excellent distinguishing indicator for depression and healthy adolescents.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Conclusions</jats:title>\n<jats:p>Our study is the first to compare RvD1 and NLRP3 between adolescent MDD and HCs. Our findings of reactive increase of RvD1 in adolescent MDD comprised a novel and critical contribution. Our results showed the presence of inflammation resolution unbalanced in adolescents with MDD and indicated that RvD1 might be an ideal biomarker for diagnosing and treating adolescent MDD.</jats:p>\n</jats:sec>", "link": "https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-05724-0", "published_date": "2024-04-15T23:00:00Z", "source": "BioMedCentral", "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Psychiatry", "authors": [ { "author_id": 348270, "given_name": "Jiamei", "family_name": "Guo", "ORCID": null, "country": null }, { "author_id": 348271, "given_name": "Tanwei", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 332698, "given_name": "Wanjun", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 348272, "given_name": "Jianyu", "family_name": "Tan", "ORCID": null, "country": null }, { "author_id": 251081, "given_name": "Xiao", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 332304, "given_name": "Anhai", "family_name": "Zheng", "ORCID": null, "country": null }, { "author_id": 348273, "given_name": "Yixiao", "family_name": "Fu", "ORCID": null, "country": null }, { "author_id": 300699, "given_name": "Tian", "family_name": "Qiu", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T16:27:08.664031Z", "noun_phrases": null, "doi": "10.1186/s12888-024-05724-0", "access": "open", "takeaways": "Inflammation is a critical pathological mechanism of Major Depressive Disorder (MDD). NLRP3 is an inflammatory pathway to maintain the immune balance. Preclinical evidence showed that Resolvin D1 might potentially offer a new option for antidepressant treatment due to its protective effects through the inhibition of neuroinflammation. Forty-eight untreated first-episode adolescent patients with MDD and 30 healthy adolescents were enrolled for this study. The patients were treated with fluoxetine for 6-", "categories": [] }, { "article_id": 283047, "title": "The causal relationship between thoracic aortic aneurysm and immune cells: a mendelian randomization study", "summary": "<jats:title>Abstract</jats:title><jats:p>One of the pathogenic causes of thoracic aortic aneurysm (TAA), a dangerous vascular condition that can cause aortic rupture, is autoimmune disorders. Currently, immune cell clustering is becoming more and more refined, and the specific immune cell phenotypes involved are yet unknown. Here, we want to clarify the causal link between TAA risk and 731 immune cell traits. There was a Mendelian randomization analysis (MR). We discovered that the presence of TAA led to an increase in CD45 on CD33<jats:sup>−</jats:sup> HLA-DR<jats:sup>−</jats:sup> myeloid cells, an increase in CD45 on natural killer cells, and a decrease in FSC-A on granulocytes after applying FDR correction. Our research also revealed a strong correlation between the incidence of TAA and an increase in immune cells with CD3 on CD39<jats:sup>+</jats:sup> CD4<jats:sup>+</jats:sup>, and CD25 on IgD<jats:sup>−</jats:sup> CD27<jats:sup>−</jats:sup> phenotypes. Through genetic techniques, our research has shown the intimate relationship between immune cells and TAA, offering direction for future clinical investigations.</jats:p>", "link": "https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-024-03876-1", "published_date": "2024-04-15T23:00:00Z", "source": "BioMedCentral", "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Cardiovascular Disorders", "authors": [ { "author_id": 348319, "given_name": "Guoli", "family_name": "Liu", "ORCID": null, "country": null }, { "author_id": 348320, "given_name": "Sha", "family_name": "Pan", "ORCID": null, "country": null }, { "author_id": 309474, "given_name": "Hongli", "family_name": "Xia", "ORCID": null, "country": null }, { "author_id": 348321, "given_name": "Mincai", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 348322, "given_name": "Ansen", "family_name": "Wu", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-16T14:27:08.304854Z", "noun_phrases": null, "doi": "10.1186/s12872-024-03876-1", "access": "restricted", "takeaways": "There is a strong correlation between the incidence of TAA and an increase in immune cells with CD3 on CD39+ CD4+ and CD25 on IgD− CD27+.", "categories": [] } ] }